Propanc Selected by OTC Markets Group to Join the OTCQB Venture Index
26 Ottobre 2015 - 5:10PM
Access Wire
MELBOURNE, AUSTRALIA / ACCESSWIRE / October 26, 2015
/ Propanc Health Group Corporation (OTCQB: PPCH)
("Propanc" or "the Company"), an emerging healthcare company
focusing on development of new and proprietary treatments for
cancer patients suffering from pancreatic and colorectal cancers,
today announced the Company was recently selected by the OTC
Markets Group to join the OTCQB Venture Index.
The OTCQB Index is designed as a benchmark for tracking the
overall performance of the OTCQB marketplace and serves primarily
as a performance benchmark for investors in OTCQB securities. The
index highlights entrepreneurial and development stage U.S. and
international companies that have been verified to trade on
OTCQB.
Further, the OTCQB Index enhances Propanc's visibility in the US
Marketplace, providing a fully transparent, highly visible
marketplace for the Company's shares.
Interestingly, in the last quarter, one hundred twenty-four were
added to the Index as more companies were approved to trade on
OTCQB under the stricter market standards and eligibility
requirements. One hundred fifty-five companies were removed during
the quarter, including 10 companies that graduated to an
exchange.
"We are very pleased to have been selected for the OTCQB Index,"
said James Nathanielsz, Propanc's Chief Executive Officer, "We are
also excited to observe that out of the ten companies which
graduated to an exchange from the OTCQB in the last quarter, at
least several appear to be from the biotech sector."
Propanc aims to fast track the development of proenzyme related
oncology products into clinical trials for colorectal and
pancreatic tumors, initially. According to Global Analyst Reports,
the world market for colorectal cancer is expected to reach $8.8
billion by 2020 and the global pancreatic cancer market is
projected to exceed $1.2 billion by 2015.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent
and Connected financial markets for 10,000 U.S. and global
securities. Through our OTC Link(R) ATS, we directly link a diverse
network of broker-dealers that provide liquidity and execution
services for a wide spectrum of securities. We organize these
securities into markets to inform investors of opportunities and
risks: the OTCQX(R) Best Market; the OTCQB(R) Venture Market; and
the OTC Pink(R) Open Market. Our data-driven platform enables
investors to easily trade through the broker of their choice at the
best possible price and empowers a broad range of companies to
improve the quality and availability of information for their
investors. To learn more about how we create better informed and
more efficient financial markets, visit www.otcmarkets.com.
About Propanc:
Propanc is currently focused on developing new cancer treatments
for patients suffering from pancreatic and colorectal cancers. We
have developed a formulation of anti-cancer compounds which exert a
number of effects designed to control or prevent tumors from
recurring and spreading throughout the body. Our products involve
or employ proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited
remaining therapeutic options for the treatment of solid tumors
such as colorectal or pancreatic tumors. In future, we intend to
develop our lead product to treat (i) early stage cancer and (ii)
pre-cancerous diseases and (iii) as a preventative measure for
patients at risk of developing cancer based on genetic screening.
For more information, visit: www.propanc.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement involve
risks and uncertainties including, without limitation, those
regarding the Company's ability to establish and maintain the
proprietary nature of its technology through the patent process,
its ability to license from others patents and patent applications,
if necessary, to develop certain products, its ability to implement
its long range business plan for various applications of its
technology, and its ability to enter into agreements with any
necessary marketing and/or distribution partners for purposes of
commercialization. This is not a solicitation to buy or sell
securities and does not purport to be an analysis of the company's
financial position. See Propanc's most recent Quarterly Report on
Form 10-Q and related 8K filings.
SOURCE:Propanc Health Group Corporation
Grafico Azioni Propanc Biopharma (PK) (USOTC:PPCB)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Propanc Biopharma (PK) (USOTC:PPCB)
Storico
Da Giu 2023 a Giu 2024